Tandem Diabetes Care Has Signed A Multi-Year Collaboration Agreement With The University Of Virginia Center For Diabetes Technology To Advance Research And Development Efforts On Fully Automated Closed-Loop Insulin Delivery Systems
Tandem Diabetes Care Has Signed A Multi-Year Collaboration Agreement With The University Of Virginia Center For Diabetes Technology To Advance Research And Development Efforts On Fully Automated Closed-Loop Insulin Delivery Systems
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced it has signed a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology (UVA) to advance research and development efforts on fully automated closed-loop insulin delivery systems.
Tandem Diabetes Care, Inc.（纳斯达克：TNDM）是一家领先的胰岛素输送和糖尿病科技公司，今天宣布与弗吉尼亚大学糖尿病科技中心（UVA）签署了一项为期多年的合作协议，以促进全面自动闭环胰岛素输送系统的研究和开发工作。
The research collaboration will rely on the UVA Center for Diabetes Technology's groundbreaking work to improve care for patients with diabetes through technology-based interventions, and its successes in translating advanced automated insulin delivery (AID) algorithms into medical devices used around the world, as well as Tandem's market leading expertise in insulin delivery devices, algorithm implementation, and data management.
该研究合作将依赖于UVA糖尿病科技中心在通过基于科技的干预措施改善糖尿病患者护理方面的开创性工作，以及在将爱文思控股的自动胰岛素输送（AID）算法转化为全球使用的医疗设备方面的成功，同时也将结合Tandem在胰岛素输送设备、算法实施和数据管理方面的行业领先专业知识。
The collaboration will expand on Tandem's ongoing research into the advancement of automated closed-loop insulin delivery technology, and will involve scientists, clinicians, and functional experts from both institutions. Results from this collaboration may lead to clinical research to accelerate approved uses for Tandem's next-generation AID systems.
此次合作将扩展Tandem在自动闭环胰岛素输送科技进步方面的持续研究，并将涉及来自双方机构的科学家、临床医生和功能专家。该合作的成果可能会导致临床研究，以加快Tandem下一代AID系统的批准使用。
